In October 2017, HemoShear and Takeda announced an exclusive drug discovery partnership for liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).  The partnership combines HemoShear’s proprietary REVEAL-Tx™ platform and ability to identify novel therapeutic targets with Takeda’s drug discovery and development capabilities.  Under the agreement, HemoShear is eligible to receive milestone payments of potentially $470 million plus royalties, and Takeda will receive the right to license and commercialize any therapeutic that results from the partnership.

Additional information regarding the partnership can be found in the press release.



In December 2018, HemoShear and Carnot BioSciences, a spin off of Smartzyme BioPharma, announced a strategic agreement to develop novel protein-based therapeutics to treat rare metabolic diseases. HemoShear’s research has shown that modifications to specific enzymes may improve the body’s ability to reduce toxins associated with metabolic diseases. This partnership leverages HemoShear’s REVEAL-Tx™ platform to identify and evaluate drug targets combined with Carnot’s expertise in directed enzyme evolution to alter specific enzymes identified by HemoShear to generate novel therapies for certain rare inborn errors of metabolism. Each company will be responsible for advancing specific programs into the clinic.

Additional information regarding the partnership can be found in the press release.



HemoShear seeks strategic partners that share our passion for developing treatments for rare metabolic disorders and improving health outcomes for patients. 

If you are interested in partnering with HemoShear, please contact us at BusinessDevelopment@hemoshear.com.